Nandrolone decanoate fda

The question of product integrity is always central in the minds of BM customers, “Can I purchase safe products from this source?” The virtually anonymity of internet sites coupled with traditionally high provider turnover rates has made answering this question even harder in today’s society. The BM is filled with “scammers”, individuals who simply set up shop to dupe customers out of money with no plan or intention of delivering on the promised AAS. These are actually the good guys, those who promote the once bitten syndrome and scare many would-be buyers/users away from further attempts at steroids. At least they have the decency (used lightly) to take your money and run. Numerous dealers run repackaging scams in which very cheap steroids are placed in expensive product labeling and sold at a premium. These less expensive forms of AAS produce greater side effects, which can be particularly dangerous to women who think they are buying a very mild steroid only to receive a significantly harsher product. Still others produce imposter or fake steroids, which are often bottles of vegetable oils labeled to look like AAS. Along the same lines are those manufactured under conditions that are far less sanitary than required by the FDA. All of the above hazards can lead to health problems ranging from minor such as abscesses and infections, to major like severe illness and death.

Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma.  If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease.  Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids.  Edema may occur occasionally with or without congestive heart failure.  Concomitant administration of adrenal steroids or ACTH may add to the edema.  In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth.  This adverse effect may result in compromised adult stature.  The younger the child the greater the risk of compromising final mature height.   The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.  This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.

If an androgen-associated adverse reaction occurs, treatment should be interrupted and, after disappearance of the symptoms, be resumed at a lower dosage. Patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be monitored, since androgens may occasionally induce salt and fluid retention. Androgens should be used cautiously in pre-pubertal boys to avoid premature epiphyseal closure or precocious sexual development. A decrease in protein bound iodine (PBI) may occur,but this has no clinical significance. Treatment of male patients over the age of approximately 50 years with androgens should be preceded by a thorough examination of prostate and baseline measurement of prostate-specific antigen serum concentration.

Nandrolone decanoate fda

nandrolone decanoate fda

Media:

nandrolone decanoate fdanandrolone decanoate fdanandrolone decanoate fdanandrolone decanoate fdanandrolone decanoate fda